United States Federal Circuit
Ariad Pharmaceuticals, Inc. v. Eli Lilly and Co., 08-1248
In a patent infringement action involving drugs related to gene regulation, district court's judgment against defendant is reversed in part and affirmed in part where: 1) the court lacked substantial evidence for its verdict that the asserted claims of plaintiff's patent were supported by adequate written description, and thus the asserted claims are invalid; and 2) the correct correctly concluded that the -516 patent was not unenforceable due to inequitable conduct.
Appellate Information
- Decided 04/03/2009
- Published 04/03/2009
Judges
Court
- United States Federal Circuit